Recently, investigators in both the CALGB 9840 trial [13] and the NSABP-B31 trial [14,15] reported responses of some Her2- breast cancers to trastuzumab and raised some controversies about the classification of breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.